BridgeMD
Comparison of iodinated contrast media injection protocols with reduced flow rates and volumes on image quality in diagnostic cerebral angiography for the evaluation of unruptured intracranial aneurysms: towards a standardization of practices (OPIAC)
EU CTIS ID: 2025-524884-18-01
What this study is testing
To demonstrate the non-inferiority of reduced-rate and reduced-volume ICM injection protocols – selectively administered via internal carotid and vertebral artery catheterisation – compared to the standard protocol currently used in Strasbourg University Hospitals, in terms of image quality for the evaluation of unruptured intracranial aneurysms in cerebral angiography.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult participant at the time of consent (age between 18 and 80 years old);
- Scheduled diagnostic cerebral angiography as part of routine care: - Initial assessment of the IA (suspected or detected in non-invasive imaging); - Follow-up of one or more IAs (treated or untreated);
- Conscious and oriented participant, able to undergo the procedure under simple local anaesthesia;
- Participant able to understand the objectives of the research and provide a dated, signed informed consent form
- Participant able to answer oral or written questions (French-speaking or understanding French)
- For women of childbearing potential: negative serum β-HCG test at the inclusion visit
You likely can't join if
- Emergency cerebral angiography
- Participants with other neurovascular conditions (AVM, AVF, etc.) in addition to an IA
- Participants with any contraindication to the use of Visipaque®
- Pregnancy or breastfeeding
- Participants whose physical or psychological condition requires sedation or general anaesthesia for the procedure
- Participants with communication or cognitive disorders
See the full eligibility criteria
- Adult participant at the time of consent (age between 18 and 80 years old);
- Scheduled diagnostic cerebral angiography as part of routine care: - Initial assessment of the IA (suspected or detected in non-invasive imaging); - Follow-up of one or more IAs (treated or untreated);
- Conscious and oriented participant, able to undergo the procedure under simple local anaesthesia;
- Participant able to understand the objectives of the research and provide a dated, signed informed consent form
- Participant able to answer oral or written questions (French-speaking or understanding French)
- For women of childbearing potential: negative serum β-HCG test at the inclusion visit
- Participant covered by a social security health insurance plan.
- Emergency cerebral angiography
- Participants with other neurovascular conditions (AVM, AVF, etc.) in addition to an IA
- Participants with any contraindication to the use of Visipaque®
- Pregnancy or breastfeeding
- Participants whose physical or psychological condition requires sedation or general anaesthesia for the procedure
- Participants with communication or cognitive disorders
- Incapable participants (subject to legal protection measures: curatorship, guardianship, judicial protection, future protection mandate, family authorization).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.